Adjuvant and neoadjuvant therapy of melanoma and other tumors

Prof. John Haanen is a renowned expert in cancer immunotherapy. From 2009 to 2018, he headed the Division of Medical Oncology at the Netherland Cancer Institute (NKI). In July 2018, he accepted a position as CSO Immunotherapy, one of the major research themes at NKI. His current research spreads over the development of cellular therapies for solid tumors, neoadjuvant immunotherapies (renal cell cancer, involvement in GI cancers, and head and neck cancers), and biomarker research. His clinical specialty is in melanoma and other skin cancers, kidney cancer, and the management of immune-related adverse events. He has co-authored over 500 peer-reviewed articles and serves on the Editorial Board of ESMO Open, Cancer Treatment Reviews, and Kidney Cancer. He is currently Editor-in-Chief of ESMO IOTECH. 

Prof. Alexander Eggermont has been General Director of Gustave Roussy Cancer Campus Grand Paris, between 2010 and 2019. There, he developed Europe’s largest Phase 1-2 drug development and immunotherapy development program amongst others. Since October 2019, he has been appointed CSO of the Princess Máxima Center for pediatric oncology. Alexander Eggermont is also Professor of Oncology at Paris-Sud University and Professor of Oncological Surgery at the Erasmus University of Rotterdam (Netherlands). In Germany, Eggermont is closely involved in the program organizing a network of comprehensive cancer centers and he holds a partial position at DKFZ-Heidelberg. Prof. Eggermont has many years of international experience in researching and treating cancer. He has won a plethora of international awards in recognition of his work in oncology, particularly in the field of immunotherapy. His past roles include being president of the EORTC, the ECCO, and the European Academy of Cancer Sciences. He is editor-in-chief of the European Journal of Cancer.